Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew S Davids

Showing results (121-130 of 225) with videos related to

Pageof 23
Sort By:
Blood Neoplasia|August 14, 2025
The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemiaYesid Alvarado-Valero, Rachel J Cook, Shira N Dinner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2018
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S Davids, Michael Hallek, William Wierda, et al.
Leukemia & Lymphoma|October 17, 2018
Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia<sup>.</sup>Matthew S Davids, Haesook T Kim, Lijian Yu, et al.
Blood|October 5, 2016
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103Chaitra S Ujjani, Sin-Ho Jung, Brandelyn Pitcher, et al.
Blood|September 30, 2025
Mechanisms of immune escape and extramedullary tropism in leukemia cutisLivius Penter, Katie Maurer, Nicoletta Cieri, et al.
American Journal of Hematology|April 8, 2026
Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-UpJennifer A Woyach, Relja Popovic, Emily L Rossi, et al.
Blood|November 17, 2021
Venetoclax plus dose-adjusted R-EPOCH for Richter syndromeMatthew S Davids, Kerry A Rogers, Svitlana Tyekucheva, et al.
Blood Advances|April 10, 2020
The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sitesAnthony Mato, Chadi Nabhan, Nicole Lamanna, et al.
Haematologica|March 30, 2019
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapyAnthony R Mato, William G Wierda, Matthew S Davids, et al.
Cancer Discovery|December 18, 2016
Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to VenetoclaxJoan Montero, Jason Stephansky, Tianyu Cai, et al.
Pageof 23

Showing results (121-130 of 225) with videos related to

Sort By:
Pageof 23
Blood Neoplasia|August 14, 2025
The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemiaYesid Alvarado-Valero, Rachel J Cook, Shira N Dinner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2018
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S Davids, Michael Hallek, William Wierda, et al.
Leukemia & Lymphoma|October 17, 2018
Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia<sup>.</sup>Matthew S Davids, Haesook T Kim, Lijian Yu, et al.
Blood|October 5, 2016
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103Chaitra S Ujjani, Sin-Ho Jung, Brandelyn Pitcher, et al.
Blood|September 30, 2025
Mechanisms of immune escape and extramedullary tropism in leukemia cutisLivius Penter, Katie Maurer, Nicoletta Cieri, et al.
American Journal of Hematology|April 8, 2026
Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-UpJennifer A Woyach, Relja Popovic, Emily L Rossi, et al.
Blood|November 17, 2021
Venetoclax plus dose-adjusted R-EPOCH for Richter syndromeMatthew S Davids, Kerry A Rogers, Svitlana Tyekucheva, et al.
Blood Advances|April 10, 2020
The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sitesAnthony Mato, Chadi Nabhan, Nicole Lamanna, et al.
Haematologica|March 30, 2019
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapyAnthony R Mato, William G Wierda, Matthew S Davids, et al.
Cancer Discovery|December 18, 2016
Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to VenetoclaxJoan Montero, Jason Stephansky, Tianyu Cai, et al.
Pageof 23